Willingness-to-pay for predictive tests with no immediate treatment implications: A survey of US residents

Health Economics

Volumn 21, Issue 3, 2012, Pages 238-251

  Neumann, Peter J ^a,b   Cohen, Joshua T ^a   Hammitt, James K ^c,e   Concannon, Thomas W ^a,b,d   Auerbach, Hannah R ^a   Fang, Chihui ^a   Kent, David M ^b,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e TOULOUSE SCHOOL OF ECONOMICS   (France)

Author keywords

Alzheimer's disease; arthritis; cancer; predictive tests; willingness to pay

Indexed keywords

ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RESIDENT; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARTHRITIS; BREAST NEOPLASMS; CHOICE BEHAVIOR; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; FINANCING, PERSONAL; HEALTH SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84856333006     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1704     Document Type: Article

References (77)

1. Andrykowski MA, Lightner R, Studts JL, Munn RK,. 1997. Hereditary cancer risk notification and testing: how interested is the general population? Journal of Clinical Oncology 15 (5): 2139-2148. (Pubitemid 27209548)
2. Asch DA, Hershey JC,. 1995. Why some health policies don't make sense at the bedside. Annals of Internal Medicine 122 (11): 846-850.
3. Asch DA, Patton JP, Hershey JC,. 1990. Knowing for the sake of knowing: the value of prognostic information. Medical Decision Making 10 (1): 47-57. (Pubitemid 20086096)
4. Babul R, Adam S, Kremer B, Dufrasne S, Wiggins S, Huggins M, Theilmann J, Bloch M, Hayden MR,. 1993. Attitudes toward direct predictive testing for the Huntington disease gene. Relevance for other adult-onset disorders. The Canadian Collaborative Group on Predictive Testing for Huntington Disease. Journal of American Medical Association 270 (19): 2321-2325. (Pubitemid 23335323)
5. Baker LC, Atlas SW, Afendulis CC,. 2008. Expanded use of imaging technology and the challenge of measuring value. Health Affairs (Millwood) 27 (6): 1467-1478.
6. Basu A, Meltzer D,. 2005. Implications of spillover effects within the family for medical cost-effectiveness analysis. Journal of Health Economics 24 (4): 751-773. (Pubitemid 40800157)
7. Benkendorf JL, Reutenauer JE, Hughes CA, Eads N, Willison J, Powers M, Lerman C,. 1997. Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. American Journal of Medical Genetics 73 (3): 296-303. (Pubitemid 27509906)
8. Berwick DM, Weinstein MC,. 1985. What do patients value? Willingness to pay for ultrasound in normal pregnancy. Medical Care 23 (7): 881-893. (Pubitemid 15058655)
9. Blackmore CC, Black WC, Jarvik JG, Langlotz CP,. 1999. A critical synopsis of the diagnostic and screening radiology outcomes literature. Academic Radiology 6 (Suppl 1): S8-18.
10. Blumenschein K, Johannesson M,. 1999. Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature. Clinical Therapeutics 21 (8): 1402-1417. (Pubitemid 29409284)
11. Bossuyt X, Verweire K, Blanckaert N,. 2007. Laboratory medicine: challenges and opportunities. Clinical Chemistry 53 (10): 1730-1733. (Pubitemid 47509664)
12. Bratt O, Damber JE, Emanuelsson M, Kristoffersson U, Lundgren R, Olsson H, Gronberg H,. 2000. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. European Journal of Cancer 36 (2): 235-241. (Pubitemid 30102201)
13. Cairns J, Shackley P, Hundley V,. 1996. Decision making with respect to diagnostic testing: a method of valuing the benefits of antenatal screening. Medical Decision Making 16 (2): 161-168. (Pubitemid 26108908)
14. Caughey AB, Washington AE, Gildengorin V, Kuppermann M,. 2004. Assessment of demand for prenatal diagnostic testing using willingness to pay. Obstetrics and Gynecology 103 (3): 539-545. (Pubitemid 40459071)
15. Chan S,. 2002. The importance of strategy for the evolving field of radiology. Radiology 224 (3): 639-648. (Pubitemid 34919792)
16. Cooke P,. 2002. Biotechnology clusters as regional, sectoral innovation systems. International Regional Science Review 25 (1): 8-37. (Pubitemid 34050407)
17. Cookson R,. 2003. Willingness to pay methods in health care: a skeptical view. Health Economics 12 (11): 891-894. (Pubitemid 37407334)
18. Dennis JM,. 2010. KnowledgePanel: processes and procedures contributing to sample representativeness and tests for self-selection bias. (Available from: http://www.knowledgenetworks.com/ganp/docs/KnowledgePanelRStatistical-Methods- Note.pdf.) Ref Type: Electronic Citation.
19. Diener A, O'Brien B, Gafni A,. 1998. Health care contingent valuation studies: a review and classification of the literature. Health Economics 7 (4): 313-326. (Pubitemid 28339960)
20. Donaldson C, Shackley P, Abdalla M,. 1997. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Economics 6 (2): 145-159. (Pubitemid 27199140)
21. Donaldson C, Shackley P, Abdalla M, Miedzybrodzka Z,. 1995. Willingness to pay for antenatal carrier screening for cystic fibrosis. Health Economics 4 (6): 439-452.
22. Drickamer MA, Lachs MS,. 1992. Should patients with Alzheimer's disease be told their diagnosis? New England Journal of Medicine 326 (14): 947-951.
23. Ellsberg D,. 1961. Risk, ambiguity, and the Savage axioms. Quarterly Journal of Economics 75: 643-669.
24. Erde EL, Nadal EC, Scholl TO,. 1988. On truth telling and the diagnosis of Alzheimer's disease. Journal of Family Practice 26 (4): 401-406.
25. Esfandyari T, Harewood GC,. 2007. Value of a negative colonoscopy in patients with non-specific gastrointestinal symptoms. Journal of Gastroenterology and Hepatology 22 (10): 1609-1614. (Pubitemid 47383329)
26. Frew E, Wolstenholme JL, Whynes DK,. 2001. Willingness-to-pay for colorectal cancer screening. European Journal of Cancer 37 (14): 1746-1751. (Pubitemid 32817048)
27. Fryback DG, Thornbury JR,. 1991. The efficacy of diagnostic imaging. Medical Decision Making 11 (2): 88-94.
28. Gilbert D,. 2009. What you don't know makes you nervous. The New York Times, 20 May 2009.
29. Green RC, Clarke VC, Thompson NJ, Woodard JL, Letz R,. 1997. Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer Disease and Associated Disorders 11 (Suppl 5): S1-5; discussion S37-39, p. S1-S5. (Pubitemid 27472530)
30. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert, SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA,. 2009. Disclosure of APOE genotype for risk of Alzheimer's disease. New England Journal of Medicine 361 (3): 245-254.
31. Grosse SD, Wordsworth S, Payne K,. 2008. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genetics in Medicine 10 (9): 648-654.
32. Gyrd-Hansen N, Rasmussen F,. 1972. [ The stability of iodophors]. Nordisk Veterinaermedicin 24 (12): 612-619.
33. Hammitt JK, Graham J,. 1999. Willingness to pay for health protection: inadequate sensitivity to probability? Journal of Risk and Uncertainty 18 (1): 33-62.
34. Hammitt JK, Liu JT,. 2004. Effects of disease type and latency on the value of mortality risk. Journal of Risk and Uncertainty 28 (1): 73-95. (Pubitemid 39014992)
35. Hammitt JK, Zhou Y,. 2006. The economic value of air-pollution-related health risks in China: a contingent valuation study. Environmental and Resource Economics 33 (3): 399-423.
36. Hanemann M, Loomis J, Kanninen B,. 1991. Statistical efficiency of double-bounded dichotomous choice contingent valuation. American Journal of Agricultural Economics 1255-1263.
37. Hanley N, Ryan M, Wright R,. 2003. Estimating the monetary value of health care: lessons from environmental economics. Health Economics 12 (1): 3-16. (Pubitemid 36149856)
38. Hillman BJ, Amis ES, Weinreb JC, Neiman HL,. 2005. The future of imaging screening: proceedings of the Fourth Annual ACR FORUM. Journal of American College of Radiology 2 (1): 43-50. (Pubitemid 40363708)
39. Hirth RA, Bloom BS, Chernew ME, Fendrick AM,. 1999. Willingness to pay for diagnostic certainty: comparing patients, physicians, and managed care executives. Journal of General Internal Medicine 14 (3): 193-195. (Pubitemid 29161779)
40. Iglehart JK,. 2006. The new era of medical imaging-progress and pitfalls. New England Journal of Medicine 354 (26): 2822-2828.
41. Kahn, J,. 1997. Ethical issues in genetic testing for Alzheimer's disease. Geriatrics 52 (Suppl 2): S30-32.
42. Kenen RH,. 1996. The at-risk health status and technology: a diagnostic invitation and the 'gift' of knowing. Social Science and Medicine 42 (11): 1545-1553. (Pubitemid 26161405)
43. Knechtges PM, Carlos RC,. 2007. The evolving role of radiologists within the health care system. Journal of American College of Radiology 4 (9): 626-635. (Pubitemid 47369294)
44. Kolata G,. 2008. $300 to learn risk of prostate cancer. The New York Times, 17 January 2008.
45. Lachaine J,. 2006. Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review. Pharmacoeconomics 24 (10): 955-970. (Pubitemid 44497468)
46. Lee DW, Neumann PJ, Rizzo JA,. 2010. Understanding the medical and nonmedical value of diagnostic testing. Value Health 13 (2): 310-314. Epub 2009 Sep 10.
47. Maguire CP, Kirby M, Coen R, Coakley D, Lawlor BA, O'Neill D,. 1996. Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis. British Medical Journal 313 (7056): 529-530. (Pubitemid 26336137)
48. Maitino AJ, Levin DC, Parker L, Rao VM, Sunshine JH,. 2003. Nationwide trends in rates of utilization of noninvasive diagnostic imaging among the Medicare population between 1993 and 1999. Radiology 227 (1): 113-117. (Pubitemid 36388727)
49. Mushlin AI, Mooney C, Grow V, Phelps CE,. 1994. The value of diagnostic information to patients with suspected multiple sclerosis. Rochester-Toronto MRI Study Group. Archives of Neurology 51 (1): 67-72. (Pubitemid 24020174)
50. National Imaging Associates. 2008. Welcome to the National Imaging Associates Web site! (Available from: www.radmd.com.) 15 January 2008.
51. Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, Tetteh NA, Kosik KS,. 2001. Public attitudes about genetic testing for Alzheimer's disease. Health Affairs (Millwood) 20 (5): 252-264. (Pubitemid 33710358)
52. Neumann PJ, Tunis SR,. 2010. Medicare and medical technology-the growing demand for relevant outcomes. New England Journal of Medicine 362 (5): 377-379.
53. Olsen JA, Smith RD,. 2001. Theory versus practice: a review of 'willingness-to-pay' in health and health care. Health Economics 10 (1): 39-52.
54. Payne K, Nicholls SG, McAllister M, MacLeod R, Ellis I, Donnai D, Davies LM,. 2007. Outcome measures for clinical genetics services: a comparison of genetics healthcare professionals and patients' views. Health Policy 84 (1): 112-122. (Pubitemid 47505265)
55. PricewaterhouseCoopers. 2006. The factors fueling rising healthcare costs.
56. Roberts JS,. 2000. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist 40 (1): 43-52. (Pubitemid 30170189)
57. Rodriguez-Monguio R, Otero MJ, Rovira J,. 2003. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 21 (9): 623-650. (Pubitemid 36808215)
58. Sach TH, Smith RD, Whynes DK,. 2007. A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow? Pharmacoeconomics 25 (2): 107-127. (Pubitemid 46175548)
59. Schonenberger E, Schnapauff D, Teige F, Laule M, Hamm B, Dewey M,. 2007. Patient acceptance of noninvasive and invasive coronary angiography. PLoS ONE 2 (2): e246.
60. Schwartz LM, Woloshin S, Fowler Jr FJ, Welch HG,. 2004. Enthusiasm for cancer screening in the United States. Journal of American Medical Association 291 (1): 71-78. (Pubitemid 38040537)
61. Seshadri S,. 2005. Why advances in imaging technology are good for radiology, patients, and the bottom line. Journal of American College of Radiology 2 (1): 5-7. (Pubitemid 40363701)
62. Shackley P,. 1996. Economic evaluation of prenatal diagnosis: a methodological review. Prenatal Diagnosis 16 (5): 389-395. (Pubitemid 26171011)
63. Shogren J,. 2005. Economics of diet and health: research challenges. Acta Agriculture Scandinavica, Section C 2 (3/4): 117-127.
64. Singer ME, Applegate KE,. 2001. Cost-effectiveness analysis in radiology. Radiology 219 (3): 611-620. (Pubitemid 32476247)
65. Smith RD,. 2003. Construction of the contingent valuation market in health care: a critical assessment. Health Economics 12 (8): 609-628. (Pubitemid 37038358)
66. Smith RD,. 2008. Contingent valuation in health care: does it matter how the 'good' is described? Health Economics 17 (5): 607-617. (Pubitemid 351772341)
67. Sunstein CR,. 1997. Bad deaths. Journal of Risk and Uncertainty 14: 259-282.
68. Swan JS, Fryback DG, Lawrence WF, Sainfort F, Hagenauer ME, Heisey DM,. 2000. A time-tradeoff method for cost-effectiveness models applied to radiology. Medical Decision Making 20 (1): 79-88. (Pubitemid 30036266)
69. Tufts Medical Center. 2010. Cost-effectiveness analysis registry. (Available from: http://www.cearegistry.org.)
70. Van Bebber S, Liang S, Phillips K, Marshall D, Walsh J, Kulin N,. 2007. Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. The Personal Medical 4: 341-350. (Pubitemid 47354517)
71. Viscusi W, Magat W, Huber J,. 1991. Communication of ambiguous risk information. Theory and Decision 31: 159-173.
72. Weinstein MC, Fineberg HV, Elstein AS, Frazier HS, Neuhauser D, Neutra RR, McNeil BJ,. 1980. Clinical Decision Analysis. W.B. Saunders: Philadelphia.
73. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB,. 1996. Recommendations of the panel on cost-effectiveness in health and medicine. Journal of American Medical Association 276 (15): 1253-1258. (Pubitemid 26337709)
74. Welkenhuysen M, Evers-Kiebooms G, Van den BH,. 1997. Attitudes toward predictive testing for Alzheimer's disease in a student population. Psychiatric Genetics 7 (3): 121-126. (Pubitemid 27450087)
75. Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, Sheps SB, Schechter MT, Hayden MR,. 1992. The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. New England Journal of Medicine 327 (20): 1401-1405.
76. Wroe AL, Salkovskis PM, Rimes KA,. 1998. The prospect of predictive testing for personal risk: attitudes and decision making. Behavioral Research and Therapy 36 (6): 599-619. (Pubitemid 28288642)
77. Yasunaga H, Ide H, Imamura T, Ohe K,. 2006a. Benefit evaluation of mass screening for prostate cancer: willingness-to-pay measurement using contingent valuation. Urology 68 (5): 1046-1050. (Pubitemid 44755438)